Bristol Myers (BMY.US) and Prime Medicine (PRME.US) collaborate to develop innovative cell therapies
Wednesday, Oct 2, 2024 8:30 pm ET
MYE --
PRME --
Prime Medicine (PRME.US) announced on September 30 that it has entered into a strategic development and license agreement with Bristol Myers (BMY.US) to co-develop next-generation T-cell therapies, combining Prime Medicine's precise multi-gene editing capabilities with Bristol Myers' expertise in developing and commercializing innovative cell therapies.